MEDINCELL S.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.5 EUR | +0.81% |
|
+12.61% | +73.61% |
| Apr. 17 | Medincell: share price rises following agreement with AbbVie | CF |
| Apr. 16 | Medincell, AbbVie to Co-Develop Injectable Therapeutics | DJ |
| Sales 2024 * | 13.96M 14.99M | Sales 2025 * | 41.88M 44.99M | Capitalization | 356M 383M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M -24.71M | Net income 2025 * | 2M 2.15M | EV / Sales 2024 * | 29 x |
| Net Debt 2024 * | 48.73M 52.35M | Net Debt 2025 * | 58.83M 63.2M | EV / Sales 2025 * | 9.92 x |
| P/E ratio 2024 * |
-13.6
x | P/E ratio 2025 * |
-207
x | Employees | 138 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.98% |
More Fundamentals
* Assessed data
More news
Latest transcript on MedinCell S.A.
More press releases
More news
| 1 day | +0.81% | ||
| 1 week | +12.61% | ||
| Current month | +30.34% | ||
| 1 month | +31.44% | ||
| 3 months | +51.70% | ||
| 6 months | +117.77% | ||
| Current year | +73.61% |
1 week
11.10
12.94
1 month
9.0512.94
Current year
6.9112.94
1 year
5.2512.94
3 years
4.7312.94
5 years
4.3520.00
10 years
4.3520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 03-01-08 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 23-08-31 |
| Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 17-07-04 |
Tone Kvåle
BRD | Director/Board Member | 55 | 22-06-12 |
Virginie Lleu
BRD | Director/Board Member | - | 16-05-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 12.5 | +0.81% | 43 042 |
| 24-04-25 | 12.4 | +2.48% | 121,673 |
| 24-04-24 | 12.1 | -1.47% | 97,316 |
| 24-04-23 | 12.28 | +6.23% | 197,954 |
| 24-04-22 | 11.56 | +4.14% | 138,202 |
Real-time Euronext Paris, April 26, 2024 at 05:29 am EDT
More quotes
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.4
EUR
Average target price
16.75
EUR
Spread / Average Target
+35.08%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +73.61% | 382M | |
| +24.84% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.32% | 233B | |
| +5.53% | 201B | |
| -10.06% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- MEDCL Stock
